Induced Suppression of Platelet Activity in Aneurysmal SAH Management
Official title: Induced Suppression of Platelet Activity in Aneurysmal SAH Management-2 (iSPASM-2)
Funded at Duke University · NIH-11628206 · Data updated 2026-11-12
A new approach tests whether carefully reducing platelet activity can improve outcomes after aneurysmal subarachnoid hemorrhage.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | September 1, 2025 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $785,816 |
| NIH project number | 4UH3NS138219-02 |
| Project ID | NIH-11628206 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults who have experienced aneurysmal subarachnoid hemorrhage and are eligible for antiplatelet therapy consideration.
✕Less likely to help
Some patients may not respond to antiplatelet strategies or may experience adverse effects; eligibility may exclude those with certain medical conditions.
What this research studies
This project at Duke University explores using targeted antiplatelet therapy to reduce microthrombosis after a brain hemorrhage caused by an aneurysm. It builds on prior evidence from a successful early trial and aims to test a refined treatment in patients who have had an aneurysmal bleed. If successful, the approach could lessen brain injury and improve recovery of daily functioning. The study uses a controlled, blinded design to compare a platelet-suppressing treatment with standard care, focused on safety and potential benefits for patients. Participation would involve specific treatment administration and monitoring during the acute/post-acute period.
Why it matters
Potential benefit: If successful, patients could have better recovery of independence and daily living abilities after aSAH.
How similar studies have gone: Prior single-center trials showed feasibility and potential benefit, but larger studies are needed to confirm effectiveness.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: Hasan, David M — Duke University
- Study coordinator: Hasan, David M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.